Administration of an anti-PD-1/PD-L1 agent at ZT18 (during active state), when PD-1-expressing TAMs peak, results in significantly increased phagocytic activity of TAMs and tumor growth suppression compared to ZT6 (during resting state at the TAM PD-1-expression nadir) [92]. This evidence concerns the gene PDCD1 and neoplasm.